Abilify vs Invega Sustenna
Side-by-side cost comparison based on Medicare Part D data
Abilify
Aripiprazole
Manufactured by Otsuka/BMS
Invega Sustenna
Paliperidone Palmitate
Manufactured by Janssen
Abilify costs 97% less per claim than Invega Sustenna ($45.00 vs $1,513.00). A generic version of Abilify is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Abilify | Invega Sustenna |
|---|---|---|
| Avg Cost Per Claim | $45.00 | $1,513.00 |
| Total Medicare Spending | $567.0M | $1.9B |
| Total Beneficiaries | 1,680,000 | 148,000 |
| Total Claims | 12,480,000 | 1,240,000 |
| Annual Cost/Patient | $338.00 | $12,676.00 |
| Year-over-Year Change | -38.4% | +4.2% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Otsuka/BMS | Janssen |
| Condition | Mental Health | Mental Health |
| Generic Name | Aripiprazole | Paliperidone Palmitate |
Abilify vs Invega Sustenna: What the Data Shows
Abilify (Aripiprazole) and Invega Sustenna (Paliperidone Palmitate) are both used to treat mental health. Based on Medicare Part D data, Abilify costs $45.00 per claim, which is 97% less than Invega Sustenna at $1,513.00 per claim.
Medicare spent $567.0M on Abilify and $1.9B on Invega Sustenna. In terms of patient reach, Abilify serves more beneficiaries (1,680,000 vs 148,000).
Year-over-year spending changed -38.4% for Abilify and +4.2% for Invega Sustenna.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Abilify is cheaper at $45.00 per claim, compared to $1,513.00 for Invega Sustenna. That makes Abilify about 97% less expensive per claim based on Medicare Part D data.
Yes, both Abilify and Invega Sustenna are used to treat mental health. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Aripiprazole and generic Paliperidone Palmitate can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Abilify covering 1,680,000 beneficiaries, and $1.9B on Invega Sustenna covering 148,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.